R&D Trends Driving Broad Change In Surging Oncology Sector
$250bn Market Forecast By 2024
Accounting for nearly a third of the global clinical pipeline, the oncology sector is set to grow to $250bn in sales by 2024 predicts a new report, identifying five research trends driving broad changes. COVID-19 has impacted trials, with 2% having been slowed down, suspended or discontinued.
You may also be interested in...
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
The end of the year should see a flurry of new products reaching the market to break new commercial ground or shake up their respective therapeutic areas. Here, Scrip takes a look at 12 of the more interesting approvals expected in the coming months, with the help of analysts at Biomedtracker.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.